O	0	6	Uptake
O	7	9	of
O	10	11	a
O	12	22	randomized
O	23	29	breast
O	30	36	cancer
O	37	47	prevention
O	48	53	trial
O	54	63	comparing
B-intervention	64	73	letrozole
O	74	76	to
B-control	77	84	placebo
O	85	87	in
O	88	93	BRCA1
O	93	94	/
O	94	95	2
O	96	105	mutations
O	106	114	carriers
O	114	115	:
O	116	119	the
O	120	125	LIBER
O	126	131	trial
O	131	132	.

O	133	138	Women
O	139	143	with
O	144	152	germline
O	153	158	BRCA1
O	159	161	or
O	162	167	BRCA2
O	168	169	(
O	169	174	BRCA1
O	174	175	/
O	175	176	2
O	176	177	)
O	178	187	mutations
O	188	191	are
O	192	202	considered
O	203	205	as
O	206	208	an
O	209	216	extreme
O	217	221	risk
O	222	232	population
O	233	236	for
O	237	247	developing
O	248	254	breast
O	255	261	cancer
O	261	262	.

O	263	275	Prophylactic
O	276	286	mastectomy
O	287	295	provides
O	296	297	a
O	298	303	valid
O	304	310	option
O	311	313	to
O	314	320	reduce
O	321	325	such
O	326	330	risk
O	330	331	,
O	332	341	impacting
O	342	349	however
O	349	350	,
O	351	354	the
O	355	362	quality
O	363	365	of
O	366	370	life
O	370	371	.

O	372	379	Medical
O	380	390	prevention
O	391	393	by
O	394	403	aromatase
O	404	413	inhibitor
O	414	418	that
O	419	422	has
O	423	427	also
O	428	436	recently
O	437	442	shown
O	443	445	to
O	446	450	have
O	451	461	preventive
O	462	468	effect
O	469	472	may
O	473	477	thus
O	478	480	be
O	481	491	considered
O	492	494	as
O	495	497	an
O	498	509	alternative
O	509	510	.

O	511	516	LIBER
O	517	519	is
O	520	522	an
O	523	530	ongoing
O	531	537	double
O	537	538	-
O	538	543	blind
O	543	544	,
O	545	555	randomized
O	556	561	phase
O	562	565	III
O	566	571	trial
O	572	574	to
O	575	583	evaluate
O	584	587	the
O	588	596	efficacy
O	597	599	of
O	600	601	5
O	601	602	-
O	602	606	year
O	607	616	letrozole
O	617	623	versus
O	624	631	placebo
O	632	634	to
O	635	643	decrease
O	644	650	breast
O	651	657	cancer
O	658	667	incidence
O	668	670	in
B-eligibility	671	675	post
I-eligibility	675	676	-
I-eligibility	676	686	menopausal
I-eligibility	687	692	BRCA1
I-eligibility	692	693	/
I-eligibility	693	694	2
I-eligibility	695	703	mutation
I-eligibility	704	712	carriers
O	713	714	(
O	714	725	NCT00673335
O	725	726	)
O	726	727	.

O	728	730	We
O	731	738	present
O	739	743	data
O	744	746	on
O	747	750	the
O	751	757	uptake
O	758	760	of
O	761	765	this
O	766	771	trial
O	771	772	.

O	773	775	We
O	776	784	compared
O	785	800	characteristics
O	801	803	of
O	804	809	women
O	810	812	in
O	813	816	the
O	817	822	LIBER
O	823	828	trial
O	829	830	(
O	830	831	n
O	832	833	=
B-total-participants	834	837	113
O	837	838	)
O	839	841	to
O	842	847	those
O	848	850	of
O	851	856	women
O	857	865	enrolled
O	866	868	in
O	869	872	the
O	873	884	prospective
O	885	892	ongoing
O	893	901	national
O	902	909	GENEPSO
O	910	916	cohort
O	917	918	(
O	918	919	n
O	920	921	=
B-total-participants	922	923	1
I-total-participants	923	924	,
I-total-participants	924	927	505
O	927	928	)
O	928	929	.

O	930	936	Uptake
O	937	940	was
O	941	950	evaluated
O	951	958	through
O	959	960	a
O	961	967	survey
O	968	972	sent
O	973	975	to
O	976	979	all
O	980	986	active
O	987	994	centres
O	994	995	,
O	996	1000	with
O	1001	1010	responses
O	1011	1019	obtained
O	1020	1024	from
O	1025	1027	17
O	1028	1030	to
O	1031	1034	the
O	1035	1037	20
O	1038	1039	(
O	1039	1041	85
O	1041	1042	%
O	1042	1043	)
O	1044	1051	centres
O	1051	1052	.

O	1053	1062	According
O	1063	1065	to
O	1066	1069	the
O	1070	1085	characteristics
O	1086	1088	of
O	1089	1092	the
O	1093	1098	women
O	1099	1107	enrolled
O	1108	1110	in
O	1111	1114	the
O	1115	1122	GENEPSO
O	1123	1129	cohort
O	1130	1133	and
O	1134	1137	the
O	1138	1144	survey
O	1144	1145	,
O	1146	1159	approximately
O	1160	1163	one
O	1163	1164	-
O	1164	1169	third
O	1170	1172	of
O	1173	1178	BRCA1
O	1178	1179	/
O	1179	1180	2
O	1181	1189	mutation
O	1190	1198	carriers
O	1199	1203	were
O	1204	1212	eligible
O	1213	1216	for
O	1217	1220	the
O	1221	1226	trial
O	1226	1227	.

B-total-participants	1228	1232	Five
I-total-participants	1233	1240	hundred
I-total-participants	1241	1244	and
I-total-participants	1245	1251	thirty
I-total-participants	1251	1252	-
I-total-participants	1252	1256	four
O	1257	1262	women
O	1263	1271	eligible
O	1272	1276	from
O	1277	1282	chart
O	1283	1289	review
O	1290	1294	have
O	1295	1299	been
O	1300	1308	informed
O	1309	1311	by
O	1312	1316	mail
O	1317	1322	about
O	1323	1326	the
O	1327	1337	prevention
O	1338	1343	trial
O	1344	1347	and
O	1348	1352	were
O	1353	1360	invited
O	1361	1363	to
O	1364	1366	an
O	1367	1371	oral
O	1372	1383	information
O	1384	1386	by
O	1387	1400	participating
O	1401	1408	centres
O	1408	1409	.

O	1410	1415	Forty
O	1415	1416	-
O	1416	1420	four
O	1421	1431	percentage
O	1432	1434	of
O	1435	1439	them
O	1440	1444	came
O	1445	1447	to
O	1448	1451	the
O	1452	1461	dedicated
O	1462	1469	medical
O	1470	1475	visit
O	1475	1476	.

B-outcome	1477	1483	Uptake
I-outcome	1484	1486	of
I-outcome	1487	1491	drug
I-outcome	1492	1502	prevention
I-outcome	1503	1508	trial
O	1509	1512	was
O	1513	1515	32
O	1515	1516	%
O	1517	1522	among
O	1523	1528	women
O	1529	1537	informed
O	1538	1544	orally
O	1545	1548	and
O	1549	1551	15
O	1551	1552	%
O	1553	1555	of
O	1556	1559	all
O	1560	1563	the
O	1564	1572	eligible
O	1573	1578	women
O	1578	1579	.

O	1580	1583	The
O	1584	1588	main
O	1589	1596	reasons
O	1597	1599	of
O	1600	1607	refusal
O	1608	1612	were
O	1612	1613	:
B-outcome	1614	1623	potential
I-outcome	1624	1628	side
I-outcome	1629	1636	effects
O	1636	1637	,
B-outcome	1638	1649	probability
I-outcome	1650	1652	to
I-outcome	1653	1660	receive
I-outcome	1661	1664	the
I-outcome	1665	1672	placebo
O	1673	1676	and
B-outcome	1677	1681	lack
I-outcome	1682	1684	of
I-outcome	1685	1692	support
I-outcome	1693	1697	from
I-outcome	1698	1703	their
I-outcome	1704	1714	physicians
O	1714	1715	.

O	1716	1728	Additionally
O	1728	1729	,
O	1730	1732	we
O	1733	1740	noticed
O	1741	1745	that
O	1746	1751	prior
O	1752	1764	prophylactic
O	1765	1777	oophorectomy
O	1778	1781	and
O	1782	1790	previous
O	1791	1801	unilateral
O	1802	1808	breast
O	1809	1815	cancer
O	1816	1820	were
O	1821	1825	more
O	1826	1834	frequent
O	1835	1837	in
O	1838	1843	women
O	1844	1852	enrolled
O	1853	1855	in
O	1856	1859	the
O	1860	1865	LIBER
O	1866	1871	trial
O	1872	1876	than
O	1877	1879	in
O	1880	1883	the
O	1884	1890	French
O	1891	1897	cohort
O	1898	1899	(
O	1899	1901	93
O	1901	1902	%
O	1903	1905	vs
O	1905	1906	.
O	1907	1909	60
O	1909	1910	%
O	1911	1914	and
O	1915	1917	50
O	1917	1918	%
O	1919	1921	vs
O	1921	1922	.
O	1923	1925	39
O	1925	1926	%
O	1926	1927	,
O	1928	1940	respectively
O	1940	1941	)
O	1941	1942	.

O	1943	1948	Based
O	1949	1951	on
O	1952	1954	an
O	1955	1962	overall
O	1963	1965	15
O	1965	1966	%
B-outcome	1967	1973	uptake
O	1974	1979	among
O	1980	1983	all
O	1984	1992	eligible
O	1993	2001	subjects
O	2001	2002	,
O	2003	2010	greater
O	2011	2014	and
O	2015	2020	wider
O	2021	2032	information
O	2033	2035	of
O	2036	2039	the
O	2040	2045	trial
O	2046	2052	should
O	2053	2055	be
O	2056	2063	offered
O	2064	2066	to
O	2067	2072	women
O	2073	2077	with
O	2078	2083	BRCA1
O	2083	2084	/
O	2084	2085	2
O	2086	2094	mutation
O	2095	2097	to
O	2098	2105	improve
O	2106	2117	recruitment
O	2117	2118	.

O	2119	2124	Women
O	2125	2129	with
O	2130	2138	previous
O	2139	2149	unilateral
O	2150	2156	breast
O	2157	2163	cancer
O	2164	2166	or
O	2167	2172	prior
O	2173	2185	prophylactic
O	2186	2198	oophorectomy
O	2199	2202	are
O	2203	2207	more
O	2208	2214	likely
O	2215	2217	to
O	2218	2223	enter
O	2224	2225	a
O	2226	2233	medical
O	2234	2244	prevention
O	2245	2250	trial
O	2250	2251	.
